✦ LIBER ✦

Life span prolongation effect of lentinan on patients with advanced or recurrent gastric cancer

✍ Scribed by T. Taguchi; H. Furue; T. Kimura; T. Kondoh; T. Hattori; I. Itoh; N. Ogawa

Publisher: Elsevier Science
Year: 1982
Tongue: English
Weight: 61 KB
Volume: 4
Category: Article
ISSN: 0192-0561
DOI: 10.1016/0192-0561(82)90142-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Life span prolongation effect of lentina

Life span prolongation effect of lentinan on patients with advanced or recurrent breast cancer

✍ T. Taguchi; O. Abe; K. Enomoto; S. Kusama; J. Tomiyama; K. Tominaga; N. Ogawa 📂 Article 📅 1982 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Effect of timing of metastasis/disease r

Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer

✍ Pooja R. Patel; James C. Yao; Kenneth Hess; Isac Schnirer; Asif Rashid; Jaffer A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Abstract ## BACKGROUND. Patients with advanced gastric cancer have a median survival (MS) of <9 months. It is unclear whether the MS of patients who have advanced cancer at the time of diagnosis (synchronous, Group A) is different from that for patients who develop advanced cancer after curativ

Exploratory analysis on the effect of ra

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

✍ McLeod, David G.; Schellhammer, Paul F.; Vogelzang, Nicholas J.; Soloway, Mark S 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## BACKGROUND. Black race has been associated with a significantly increased risk of prostate cancer mortality. This exploratory analysis investigated the effect of race on the clinical outcome of combined androgen blockade (CAB). METHODS. Data for analysis were obtained from a double-blind, rando

Impacts of fluorouracil-metabolizing enz

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer

✍ Wasaburo Koizumi; Satoshi Tanabe; Mizutomo Azuma; Kenji Ishido; Ken Nishimura; T 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 267 KB

## Abstract A phase III trial of S‐1 plus cisplatin (SP) __versus__ S‐1 alone, for first‐line treatment of advanced gastric cancer (SPIRITS trial), has shown that overall survival was better in patients treated with SP than with S‐1 alone. In the present retrospective biomarker study, we aimed to d